Progress perspective treatment lung (7 Ergebnisse)
Verlag: Springer,, 1999
- Hardcover
Anbieter: Antiquariat Knacke, Berlin, DeutschlandAntiquariat Knacke
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Gebraucht
EUR 25,00
EUR 12,00 VersandVersand von Deutschland nach USAAnzahl: 2 verfügbar
In den WarenkorbSprache: Englisch Pappband. Noch eingeschweißtes Exemplar.

- Hardcover
Anbieter: Roland Antiquariat UG haftungsbeschränkt, Weinheim, DeutschlandRoland Antiquariat UG haftungsbeschränkt
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht
EUR 75,90
EUR 42,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Hardcover: 19.3 x 0 x 27 cm. 1999. 290 p. Unread book. Like new! 9783540625483 Sprache: Englisch Gewicht in Gramm: 939.

- Softcover
Anbieter: preigu, Osnabrück, Deutschlandpreigu
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 140,10
EUR 70,00 VersandVersand von Deutschland nach USAAnzahl: 5 verfügbar
Taschenbuch. Zustand: Neu. Progress and Perspective in the Treatment of Lung Cancer | Paul Van Houtte (u. a.) | Taschenbuch | Medical Radiology | x | Englisch | 2011 | Springer | EAN 9783642641404 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

- Softcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 183,30
EUR 35,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Lung cancer is not a single disease process but is a group of biologically variable diseases. Therefore, accurate and complete diagnosis along with complete workup of the patient prior to decision-making in treatment is essential to devise the most appropriate treatment strategy. In North America adenocarcinoma of the lung now accounts for about 40% of all lung cancers and stage for stage these tumors have a poorer prognosis than squamous cell cancers of the lung. Many prognostic indicators have been identified such as genetic markers and neuroen docrine differentiation, which have important roles to play in identifying the patients who would benefit most from active treatment. Screening and early detection have been thought to be sine qua non in early diagnosis of lung cancer. However, a number of controlled trials assessing the value of annual screening for lung cancer have demonstrated in some studies that chest X-rays and/or cytology screening may improve stage distribution, resectability, survival, and fatality but has not shown an impact on disease-specific mortality rates. The Mayo Clinic lung project compar ing quarterly chest X-rays and sputum cytology with routine care in more than 10 000 male smokers indicated that 5-year survival following treatment in the screened patients was better than rates in contemporary clinical practice. However, arguments have been ad vanced as to factors that might have biased the clinical benefits. Other trials are currently under way to deal with this issue along with new molecular markers that may enhance sputum sensitivity.…

- Softcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 183,30
EUR 35,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Lung cancer is not a single disease process but is a group of biologically variable diseases. Therefore, accurate and complete diagnosis along with complete workup of the patient prior to decision-making in treatment is essential to devise the most appropriate treatment strategy. In North America adenocarcinoma of the lung now accounts for about 40% of all lung cancers and stage for stage these tumors have a poorer prognosis than squamous cell cancers of the lung. Many prognostic indicators have been identified such as genetic markers and neuroen docrine differentiation, which have important roles to play in identifying the patients who would benefit most from active treatment. Screening and early detection have been thought to be sine qua non in early diagnosis of lung cancer. However, a number of controlled trials assessing the value of annual screening for lung cancer have demonstrated in some studies that chest X-rays and/or cytology screening may improve stage distribution, resectability, survival, and fatality but has not shown an impact on disease-specific mortality rates. The Mayo Clinic lung project compar ing quarterly chest X-rays and sputum cytology with routine care in more than 10 000 male smokers indicated that 5-year survival following treatment in the screened patients was better than rates in contemporary clinical practice. However, arguments have been ad vanced as to factors that might have biased the clinical benefits. Other trials are currently under way to deal with this issue along with new molecular markers that may enhance sputum sensitivity.…

- Hardcover
Anbieter: BUCHSERVICE / ANTIQUARIAT Lars Lutzer, Wahlstedt, DeutschlandBUCHSERVICE / ANTIQUARIAT Lars Lutzer
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Gut
EUR 199,90
EUR 39,95 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Zustand: gut. 1999. Progress and Perspective in the Treatment of Lung Cancer (Medical Radiology) In deutscher Sprache. pages.

Progress and Perspective in the Treatment of Lung Cancer (Medical Radiology / Radiation Oncology)
Van Houtte, Paul (Editor) / Klastersky, J. (Editor) / Rocmans, P. (Editor) / Brady, L.W. (Foreword) / Heilmann, H.-P. (Foreword)
- Softcover
Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 253,32
EUR 14,93 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 1 verfügbar
Paperback. Zustand: Brand New. reprint edition. 290 pages. 10.63x0.70x7.60 inches. In Stock.